var data={"title":"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamides, and ketolides","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamides, and ketolides</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/contributors\" class=\"contributor contributor_credentials\">Daniel M Musher, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/contributors\" class=\"contributor contributor_credentials\">Sheila Bond, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 16, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Streptococcus pneumoniae</em> (pneumococcus), the most common cause of bacterial respiratory tract infections in children and adults, was susceptible to virtually all antibiotics used in treating such infections until outbreaks of infection due to antibiotic-resistant pneumococci were recognized in South Africa in the late 1970s [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Although the responsible organisms were called penicillin-resistant pneumococci (PRP), they had acquired genetic material that encoded resistance both to penicillin and to other commonly used antibiotics.</p><p>In the ensuing decades, resistance of pneumococci to several clinically relevant classes of antibiotics has evolved from an ominous medical curiosity to a worldwide health problem.</p><p>Macrolides, azalides, lincosamides, and ketolides are related drugs that inhibit protein synthesis at the same site in the bacterial ribosome and are generally active against the same microorganisms. Macrolides, azalides, and ketolides are (or, at least, used to be) generally active against <em>S. pneumoniae</em>, <em>Haemophilus influenzae</em>, <em>Moraxella catarrhalis</em>, <em>Legionella</em> species, <em>Chlamydia pneumoniae</em>, and <em>Mycoplasma pneumoniae</em>. <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a>, the only lincosamide currently in use, is effective against most pneumococci but is not active against such pathogens as <em>H. influenzae</em> and <em>M. catarrhalis</em>.</p><p>The mechanisms of action of and resistance of pneumococci to macrolides, azalides, lincosamides, and ketolides, as well as clinical data on the outcome of therapy with these drugs for otitis, sinusitis, acute exacerbations of chronic bronchitis, pneumonia, and meningitis, will be reviewed here. Resistance to the other classes of drugs is discussed separately. (See <a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">&quot;Resistance of Streptococcus pneumoniae to beta-lactam antibiotics&quot;</a> and <a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-the-fluoroquinolones-doxycycline-and-trimethoprim-sulfamethoxazole\" class=\"medical medical_review\">&quot;Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MACROLIDES AND AZALIDES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The first of the macrolides, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, is poorly tolerated. After oral administration, erythromycin causes gastrointestinal distress and is not reliably absorbed; it also frequently causes thrombophlebitis after intravenous administration. As a result, erythromycin has been largely replaced by <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, a newer macrolide, and <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a>, an azalide. It is important to note that most pneumococci that are resistant to erythromycin are also resistant to the newer macrolides and the azalides.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanisms of action and resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Macrolides and azalides insert into a pocket of the 23S subunit of the 50S ribosome specifically by attaching at domain V of the peptidyl transferase loop, thereby blocking protein assembly. In doing so, these drugs exert a bactericidal effect on <em>S. pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>Acquisition of genetic material, designated <em>ermB </em>or <em>mefA</em>, encodes for resistance to macrolides and azalides [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/3,4\" class=\"abstract_t\">3,4</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>ermB</em> encodes methylation of a base in domain V of the 23S rRNA (A2058) that alters the site of attachment such that the macrolide no longer recognizes and binds to the ribosome. This lack of binding creates high-level resistance (&gt;64 <span class=\"nowrap\">mcg/mL);</span> thus, increasing the dose with a resulting increase in the concentration of the drug has little effect.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>mefA</em> encodes a pump that the organism uses to expel macrolides. This resistance is at a lower level (usually &lt;16 <span class=\"nowrap\">mcg/mL);</span> high antibiotic concentrations might be expected to overcome the pump, forcing enough antibiotic into the bacterium to exert an antibacterial effect. <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">Clarithromycin</a> and <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> are more active against pneumococci than is <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, and it has been thought that they might be effective in vivo against <em>mefA</em>-containing strains. However, the level of resistance in these strains has been rising [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/5\" class=\"abstract_t\">5</a>], and it seems increasingly likely that the resistance observed in vitro will be clinically meaningful.</p><p/><p>Some resistant isolates carry both <em>ermB</em> and <em>mefA</em>. In a small percentage of isolates, other mutations induce resistance, for example, by causing other base substitutions in domain V or by altering protein sequences within or adjacent to the macrolide binding site, especially involving ribosomal proteins L4 and L22 [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Prevalence of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In 1998, only 18 percent of pneumococcal isolates were resistant to macrolides [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/8\" class=\"abstract_t\">8</a>]. Between 1998 and 2011, there was a steady increase in the rate of resistance such that, in 2011, 25 to 45 percent of pneumococci in the United States were resistant to macrolides. By 2013, resistance rates were on average about 30 percent in the United States [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/9,10\" class=\"abstract_t\">9,10</a>].</p><p>For reasons that are unexplained, there is substantial <a href=\"https://resistancemap.cddep.org/CountryPageSub.php?countryId=38&country=United+States&amp;token=ChoKhAb3KcQzKnVjFV17tBQhD07U9lnNcaeVCs0Uzkv7h5GjLiOH6Tk7htAHrcE9tXtvoau8w3lwekbGlu9chbet+1JKB+ZkJDeEb/2Fj/waHwDB3IZjxQNcRVajR9DZ&amp;TOPIC_ID=7033\" target=\"_blank\" class=\"external\">regional variation</a> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Resistance is attributable to <em>mefA</em> and <em>ermB</em> in approximately equal numbers of isolates, with about 25 percent of them carrying both elements [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Although the introduction of the pneumococcal conjugate vaccine into the vaccine schedule for children in the United States in 2000 was anticipated to reduce resistance by leading to the elimination of resistant nasal carriage strains, this appears not to have been the case, since &quot;replacement&quot; strains that have emerged also have a high rate of resistance [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/13\" class=\"abstract_t\">13</a>].</p><p>A higher proportion of pneumococci in Europe are macrolide resistant and, in the majority of phenotypically resistant isolates, <em>ermB</em> is responsible [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/14\" class=\"abstract_t\">14</a>]. Rates of resistance are lower in Canada than in the United States and higher in the Far East than in Europe [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/15-17\" class=\"abstract_t\">15-17</a>]. The rates of <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a> resistance in Asia were 55 percent overall, 92 percent in Vietnam, and 70 percent in Japan [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/16,17\" class=\"abstract_t\">16,17</a>]. In the study from Japan, half of the isolates were highly resistant (minimum inhibitory concentration [MIC] &ge;16 <span class=\"nowrap\">mcg/mL),</span> and resistance was most frequently identified among children younger than two years of age [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/17\" class=\"abstract_t\">17</a>]. Similarly, high rates of resistance are now reported in Eastern Europe as well [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/18\" class=\"abstract_t\">18</a>].</p><p>A prospective cohort study of several thousand patients with invasive pneumococcal infection identified apparent risk factors for the acquisition of macrolide-resistant pneumococcal strains [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/19\" class=\"abstract_t\">19</a>]. These include previous use of <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (odds ratio [OR] 9.9), <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (OR 3.9), penicillin (OR 1.8), and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (OR 2.1).</p><p>In another study, following mass <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> administration (a single dose of 20 <span class=\"nowrap\">mg/kg</span> every three months for one year) for trachoma in children in Ethiopia, the diversity of pneumococcal sequence types detected by multilocus sequence typing of nasopharyngeal swab specimens decreased significantly, and resistant clones present before mass azithromycin administration increased in frequency (from 5 percent before treatment to 15 percent after treatment) [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/20\" class=\"abstract_t\">20</a>]. These results support the hypothesis that antibiotic selection pressure results in clonal expansion of existing resistant strains among pneumococci colonizing the nasopharynx.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Resistance and the outcome of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although careful studies of otitis media have established a close relationship between the susceptibility of the infecting pneumococcus and the response to macrolides [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/21-23\" class=\"abstract_t\">21-23</a>], the relationship among drug levels, inhibitory concentrations, and clinical outcome has been less clear in cases of pneumonia. This is largely due to the fact that most studies of pneumonia focus on community-acquired pneumonia (CAP), in which an etiologic agent is often not established, and treatment regimens frequently combine a macrolide with a second antibiotic. Even when the use of macrolide monotherapy has been reported, the absence of an identified etiologic agent renders it impossible to interpret the results [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/24\" class=\"abstract_t\">24</a>]. In evaluating reports of responses to therapy, it is essential to note the years during which patients were studied and the prevailing rate and level of resistance at those times, which is clearly a &quot;moving target&quot; in recent years.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Otitis media</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>One review summarized an extensive clinical experience by stating that <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> cured nearly 95 percent of cases of otitis media when the organisms were susceptible to the drug but only 20 percent when they were not [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/23\" class=\"abstract_t\">23</a>]. In one study, for example, azithromycin (10 <span class=\"nowrap\">mg/kg</span> on the first day and 5 <span class=\"nowrap\">mg/kg</span> for four additional days) cured 23 of 25 children who had pneumococcal otitis media due to a fully susceptible organism (MIC &lt;0.5 <span class=\"nowrap\">mcg/mL)</span> compared with 3 of 8 children whose infecting organism was only susceptible to &gt;2 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/21\" class=\"abstract_t\">21</a>]. Unpublished data from the manufacturer of azithromycin suggest that 30 <span class=\"nowrap\">mg/kg</span> as a single dose cures 85 percent of cases of pneumococcal otitis media, a finding that was consistent with the national rate (at the time the study was done) of 8 percent <em>ermB</em>-mediated resistance to macrolides. (See <a href=\"topic.htm?path=acute-otitis-media-in-children-treatment\" class=\"medical medical_review\">&quot;Acute otitis media in children: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Sinusitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some studies, <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (500 mg daily for 3 to 5 days) or <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (500 mg twice daily for 10 to 14 days) effectively treated patients with acute bacterial sinusitis [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/25,26\" class=\"abstract_t\">25,26</a>]. A study from Croatia where, at the time, 25 percent of pneumococci were <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a> resistant [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/27\" class=\"abstract_t\">27</a>] showed a 95 percent cure rate by azithromycin [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/28\" class=\"abstract_t\">28</a>]. These results might support the notion of a discrepancy between in vitro and in vivo resistance to this class of drugs, but a limitation of such studies is that most cases of sinusitis eventually resolve spontaneously, and the outcome of any study is determined by the severity of disease in the patients who are included. At the present time, macrolides are <strong>not</strong> recommended for empiric therapy of bacterial sinusitis. This is discussed in detail separately. (See <a href=\"topic.htm?path=uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment\" class=\"medical medical_review\">&quot;Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Pneumonia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most of the literature on macrolide resistance in pneumonia deals with groups of patients who are lumped together under the diagnosis of &quot;community-acquired pneumonia.&quot; Some proportion of these patients may be infected with <em>S. pneumoniae</em>, but many others may not be, and an uncertain but probably large proportion of nonsevere pneumonias may resolve without therapy. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-microbiology-of-community-acquired-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults&quot;</a>.)</p><p>Oral <a href=\"topic.htm?path=azithromycin-drug-information\" class=\"drug drug_general\">azithromycin</a> (500 mg on the first day followed by 250 mg daily for 4 more days) or <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a> (500 mg twice daily for 10 days) have been used effectively to treat CAP in outpatients [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/24,29-31\" class=\"abstract_t\">24,29-31</a>]. The 2007 Infectious Diseases Society of America and American Thoracic Society guidelines for the treatment of CAP use a 25 percent rate of high-level (&ge;16 <span class=\"nowrap\">mcg/mL)</span> macrolide resistance of pneumococcal isolates as the threshold at which this class should not be used for empiric monotherapy of CAP; the use of macrolide monotherapy for CAP should be limited to patients not requiring hospitalization and who have no significant comorbidities <span class=\"nowrap\">and/or</span> use of antibiotics within the last three months [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/32\" class=\"abstract_t\">32</a>]. This threshold has been reached in most countries. However, the overall prevalence of pneumococcal pneumonia is declining [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/33,34\" class=\"abstract_t\">33,34</a>]. Whether macrolides remain appropriate first-line therapy is an open question and knowledge is evolving [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-in-the-outpatient-setting#H11\" class=\"medical medical_review\">&quot;Treatment of community-acquired pneumonia in adults in the outpatient setting&quot;, section on 'Treatment regimens'</a>.)</p><p>Macrolide monotherapy is not recommended for the treatment of hospitalized patients with CAP, but macrolides and azalides are commonly used in the United States as part of a combination regimen. (See <a href=\"topic.htm?path=antibiotic-studies-for-the-treatment-of-community-acquired-pneumonia-in-adults#H12\" class=\"medical medical_review\">&quot;Antibiotic studies for the treatment of community-acquired pneumonia in adults&quot;, section on 'Macrolides versus other drugs'</a> and <a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization\" class=\"medical medical_review\">&quot;Treatment of community-acquired pneumonia in adults who require hospitalization&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">LINCOSAMIDES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> is the only lincosamide in current use.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Mechanisms of action and resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although structurally different from the macrolides, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> acts at the same site in the ribosome, and its activity is blocked if the site is methylated; thus, pneumococci that have the <em>ermB</em> mutation are also resistant to clindamycin. However, this drug is not excluded from bacterial cells by the efflux pump, and <em>mefA</em> does not convey resistance.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Prevalence of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 5 to 10 percent of pneumococci in the United States are resistant to <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> with regional variation, as noted above [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Treatment and response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based upon relatively limited clinical data, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> provides effective therapy for pneumococcal pneumonia due to susceptible isolates [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/37\" class=\"abstract_t\">37</a>], but it is not recommended for pneumonia of uncertain etiology because of the lack of efficacy against other common pathogens such as <em>H. influenzae</em>, <em>M. catarrhalis</em>, <em>Legionella</em> spp, and <em>Mycoplasma pneumoniae</em>.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">KETOLIDES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">Telithromycin</a>, the only ketolide marketed in the United States to date, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with sinusitis, acute exacerbation of chronic bronchitis, and community-acquired pneumonia (CAP) in April 2004.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Warning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of the possible side effects of severe hepatotoxicity [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/38\" class=\"abstract_t\">38</a>], visual disturbances, and serious exacerbation of myasthenia gravis, a federal advisory panel in December 2006 concluded that <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a> should be a secondary alternative to other antimicrobial drugs for the treatment of mild to moderate pneumonia. (See <a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin#H12\" class=\"medical medical_review\">&quot;Azithromycin, clarithromycin, and telithromycin&quot;, section on 'Warnings about telithromycin'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The ketolides have two sites of action against <em>S. pneumoniae</em>. One is at domain V, as described above for the macrolides. However, the ketolides have a greater affinity than the macrolides for that site and, thus, have a much lower minimum inhibitory concentration (MIC) for most organisms [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/39\" class=\"abstract_t\">39</a>]. A second binding site is at domain II of the 23s ribosome, one that involves the same pocket of insertion but to which macrolides do not bind [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/40\" class=\"abstract_t\">40</a>]. Thus, pneumococci that have <em>ermB</em> do not bind ketolides at domain V but still do bind at domain II, thereby explaining how ketolides remain active against these strains. In addition, ketolides have low affinity for the efflux pump protein, and, therefore, isolates that contain <em>mefA</em> are not resistant.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Susceptibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Ketolides are active in vitro against both macrolide-susceptible and macrolide-resistant strains of <em>S. pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/39,41\" class=\"abstract_t\">39,41</a>]. As an example, in a large study of pneumococci from Croatia where high-level macrolide resistance is prevalent, 99.8 percent of pneumococci were susceptible to <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/41\" class=\"abstract_t\">41</a>]. Ketolides are also active against <em>Legionella</em> spp [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/42\" class=\"abstract_t\">42</a>], <em>Chlamydia pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/43\" class=\"abstract_t\">43</a>], and <em>Mycoplasma pneumoniae</em> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/42,44\" class=\"abstract_t\">42,44</a>] in vitro. Telithromycin-resistant pneumococci have already been isolated [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/45\" class=\"abstract_t\">45</a>], however, and it is anticipated that the prevalence of such strains will increase in proportion to ketolide use.</p><p>A survey of 1817 <em>S. pneumoniae</em> isolates collected during the winter of 2002 to 2003 from 44 United States medical centers found no resistance to <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a> [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/36\" class=\"abstract_t\">36</a>]. Subsequently, <em>S. pneumoniae</em> strains with reduced susceptibility have been reported [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/46\" class=\"abstract_t\">46</a>], but resistance remains rare [<a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/47,48\" class=\"abstract_t\">47,48</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The macrolides were important agents for treating otitis media, sinusitis, and outpatients with community-acquired pneumonia (CAP) in the past, in large measure because of their excellent activity against pneumococci. However, increases in the proportion of pneumococci that are resistant to macrolides have reduced the utility of macrolides for these conditions. (See <a href=\"#H2\" class=\"local\">'Macrolides and azalides'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> is effective against pneumococci that have <em>mefA</em> resistance but not against those that have <em>ermB</em>; the lack of activity against other respiratory pathogens (eg, <em>Haemophilus influenzae</em>) limits the utility of this drug in CAP unless pneumococci are known to be responsible. (See <a href=\"#H9\" class=\"local\">'Lincosamides'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although <a href=\"topic.htm?path=telithromycin-drug-information\" class=\"drug drug_general\">telithromycin</a> has activity against most pneumococci, its use should be limited to a secondary alternative to other agents because of the potential for severe toxicity. (See <a href=\"#H14\" class=\"local\">'Warning'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/1\" class=\"nounderline abstract_t\">Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagn Microbiol Infect Dis 1997; 28:131.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/2\" class=\"nounderline abstract_t\">Berry V, Thorburn CE, Knott SJ, Woodnutt G. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother 1998; 42:3193.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/3\" class=\"nounderline abstract_t\">Corso A, Severina EP, Petruk VF, et al. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist 1998; 4:325.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/4\" class=\"nounderline abstract_t\">Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999; 29:1186.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/5\" class=\"nounderline abstract_t\">Stephens DS, Zughaier SM, Whitney CG, et al. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet 2005; 365:855.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/6\" class=\"nounderline abstract_t\">Tait-Kamradt A, Davies T, Appelbaum PC, et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44:3395.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/7\" class=\"nounderline abstract_t\">Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:630.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/8\" class=\"nounderline abstract_t\">Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013; 75:107.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/9\" class=\"nounderline abstract_t\">Kim L, McGee L, Tomczyk S, Beall B. Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective. Clin Microbiol Rev 2016; 29:525.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/ (Accessed on October 16, 2017).</li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/11\" class=\"nounderline abstract_t\">Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009; 48:e23.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/12\" class=\"nounderline abstract_t\">Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15:1260.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/13\" class=\"nounderline abstract_t\">Sim&otilde;es AS, Pereira L, Nunes S, et al. Clonal evolution leading to maintenance of antibiotic resistance rates among colonizing Pneumococci in the PCV7 era in Portugal. J Clin Microbiol 2011; 49:2810.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/14\" class=\"nounderline abstract_t\">P&eacute;rez-Trallero E, Fern&aacute;ndez-Mazarrasa C, Garc&iacute;a-Rey C, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45:3334.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/15\" class=\"nounderline abstract_t\">Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl 2:S81.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/16\" class=\"nounderline abstract_t\">Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48:2101.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/17\" class=\"nounderline abstract_t\">Hotomi M, Billal DS, Shimada J, et al. Increase of macrolide-resistant Streptococcus pneumoniae-expressing mefE or ermB gene in the nasopharynx among children with otitis media. Laryngoscope 2005; 115:317.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/18\" class=\"nounderline abstract_t\">Mykhalko YO, Duhovych TV, Kish PP. Susceptibility of streptococcus pneumoniae to fluoroquinolones and macrolides in upper respiratory tract infections. Wiad Lek 2017; 70:224.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/19\" class=\"nounderline abstract_t\">Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/20\" class=\"nounderline abstract_t\">Keenan JD, Klugman KP, McGee L, et al. Evidence for clonal expansion after antibiotic selection pressure: pneumococcal multilocus sequence types before and after mass azithromycin treatments. J Infect Dis 2015; 211:988.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/21\" class=\"nounderline abstract_t\">Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/22\" class=\"nounderline abstract_t\">Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/23\" class=\"nounderline abstract_t\">Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical significance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000; 19:S57.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/24\" class=\"nounderline abstract_t\">Kogan R, Mart&iacute;nez MA, Rubilar L, et al. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr Pulmonol 2003; 35:91.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/25\" class=\"nounderline abstract_t\">Hayle R, Lingaas E, H&oslash;ivik HO, Odeg&aring;rd T. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1996; 15:849.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/26\" class=\"nounderline abstract_t\">Murray JJ, Solomon E, McCluskey D, et al. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther 2000; 22:1421.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/27\" class=\"nounderline abstract_t\">Tambic Andrasevic A, Tambic T, Kalenic S, et al. Surveillance for antimicrobial resistance in Croatia. Emerg Infect Dis 2002; 8:14.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/28\" class=\"nounderline abstract_t\">Klapan I, Culig J, Oreskovi&#263; K, et al. Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999; 20:7.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/29\" class=\"nounderline abstract_t\">Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000; 44:1796.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/30\" class=\"nounderline abstract_t\">Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14:182.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/31\" class=\"nounderline abstract_t\">Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122:1271.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/32\" class=\"nounderline abstract_t\">Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/33\" class=\"nounderline abstract_t\">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/34\" class=\"nounderline abstract_t\">Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis 2017; 65:1736.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/35\" class=\"nounderline abstract_t\">Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2015; 372:294.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/36\" class=\"nounderline abstract_t\">Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/37\" class=\"nounderline abstract_t\">Cherubin CE, Magazine D, Hargrove C, et al. A comparative study of the treatment of presumed pneumococcal pneumonia: parenteral penicillin and clindamycin with continuation on oral therapy. Curr Ther Res Clin Exp 1975; 17:88.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/38\" class=\"nounderline abstract_t\">Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/39\" class=\"nounderline abstract_t\">Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42:624.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/40\" class=\"nounderline abstract_t\">Xiong L, Shah S, Mauvais P, Mankin AS. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol Microbiol 1999; 31:633.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/41\" class=\"nounderline abstract_t\">Nagai K, Appelbaum PC, Davies TA, et al. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries. Antimicrob Agents Chemother 2002; 46:371.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/42\" class=\"nounderline abstract_t\">Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43:90.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/43\" class=\"nounderline abstract_t\">Miyashita N, Fukano H, Niki Y, Matsushima T. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48:403.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/44\" class=\"nounderline abstract_t\">Yamaguchi T, Hirakata Y, Izumikawa K, et al. In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan. Antimicrob Agents Chemother 2000; 44:1381.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/45\" class=\"nounderline abstract_t\">Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US--an update. Clin Infect Dis 2004; 39 Suppl 3:S142.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/46\" class=\"nounderline abstract_t\">Takaya A, Kitagawa N, Kuroe Y, et al. Mutational analysis of reduced telithromycin susceptibility of Streptococcus pneumoniae isolated clinically in Japan. FEMS Microbiol Lett 2010; 307:87.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/47\" class=\"nounderline abstract_t\">Flamm RK, Rhomberg PR, Sader HS. In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program. Antimicrob Agents Chemother 2017; 61.</a></li><li><a href=\"https://www.uptodate.com/contents/resistance-of-streptococcus-pneumoniae-to-the-macrolides-azalides-lincosamides-and-ketolides/abstract/48\" class=\"nounderline abstract_t\">Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003-2004). Diagn Microbiol Infect Dis 2009; 63:302.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7033 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MACROLIDES AND AZALIDES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanisms of action and resistance</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Prevalence of resistance</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Resistance and the outcome of therapy</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">- Otitis media</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Sinusitis</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Pneumonia</a></li></ul></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">LINCOSAMIDES</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Mechanisms of action and resistance</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Prevalence of resistance</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Treatment and response</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">KETOLIDES</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Warning</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Mechanism of action</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Susceptibility</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-otitis-media-in-children-treatment\" class=\"medical medical_review\">Acute otitis media in children: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antibiotic-studies-for-the-treatment-of-community-acquired-pneumonia-in-adults\" class=\"medical medical_review\">Antibiotic studies for the treatment of community-acquired pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">Azithromycin, clarithromycin, and telithromycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-microbiology-of-community-acquired-pneumonia-in-adults\" class=\"medical medical_review\">Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-beta-lactam-antibiotics\" class=\"medical medical_review\">Resistance of Streptococcus pneumoniae to beta-lactam antibiotics</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=resistance-of-streptococcus-pneumoniae-to-the-fluoroquinolones-doxycycline-and-trimethoprim-sulfamethoxazole\" class=\"medical medical_review\">Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-in-the-outpatient-setting\" class=\"medical medical_review\">Treatment of community-acquired pneumonia in adults in the outpatient setting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-community-acquired-pneumonia-in-adults-who-require-hospitalization\" class=\"medical medical_review\">Treatment of community-acquired pneumonia in adults who require hospitalization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment\" class=\"medical medical_review\">Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment</a></li></ul></div></div>","javascript":null}